The strong Phase 2 data in a difficult-to-treat population with FDA designations already in place significantly de-risks the path to approval. Triggers potential for near-term value inflection with planned 2026 BLA filing. Monitor for Phase 3 readout in breast cancer (DYNASTY-Breast02) later this year which could expand the market opportunity.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $96.70entry
- T+1 · 7mo ago +1.77%α +0.56% · $98.41
- T+5 · 7mo ago +8.78%α +5.48% · $105.19
- T+20 · 6mo ago −3.47%α −11.20% · $93.34
- T+60 · 4mo ago −3.28%α −12.20% · $93.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival. The data support advancement toward a 2026 BLA filing, with a confirmatory Phase 3 trial ongoing.
Key Facts
- Trastuzumab pamirtecan met primary efficacy endpoint in Phase 2 cohort of 145 patients with HER2-expressing, recurrent endometrial cancer
- Confirmed objective response rate was 47.9% in centrally tested patients (n=96) with median progression-free survival of 8.1 months
- Drug showed activity across all HER2 expression levels including IHC1+ and IHC2+, addressing high unmet need where standard chemo has only 15% response rate
- Safety profile was manageable with 46.9% grade 3 treatment-related adverse events and 4.8% grade 3 interstitial lung disease
- Fast Track and Breakthrough Therapy designations received from FDA in 2023; BLA planned for 2026 subject to regulatory feedback
Financial Impact
Significant potential revenue upside from a new oncology product in a high-unmet-need population with potential for accelerated approval. Phase 3 trial Fern-EC-01 ongoing.
Risk Factors
- Phase 3 confirmatory trial (Fern-EC-01) must validate these results for full approval
- Safety signals including 4.8% grade 3 ILD require careful risk-benefit assessment in broader populations
- Competition from other HER2-targeted therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000027 |
| Document: form6-ktpamecdatasgo202613.htm | 0001776985-26-000027 |
| Document: 0001776985-26-000027-index-headers.html | 0001776985-26-000027 |
| Document: 0001776985-26-000027-index.html | 0001776985-26-000027 |
| Document: 0001776985-26-000027.txt | 0001776985-26-000027 |
Track record
38 reports on BNTX
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers